Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
GlobeNewswire
IMCIVREE expected to be funded and available for use in England and Wales within three months through the National Health Service..